FDA Extends Approval for Alirocumab to Lower LDL-C in Pediatric Patients with HeFHÂ
Addressing an Unmet Need in Pediatric Patients with HeFH Heterozygous familial hypercholesterolemia (HeFH) affects about 1 in 313 people—characterized by dangerously high low-density lipoprotein cholesterol (LDL-C) levels. Untreated, it can trigger early heart disease. Detecting and treating it early in pediatric patients can prevent heart problems later. American College of Cardiology/American Heart Association guidelines define acceptable LDL-C […]
